Optimind Pharma Corp. (CSE:OMND)
Canada · Delayed Price · Currency is CAD 0.0050
-0.0050 (-50.00%)
Aug 19, 2025, 1:59 PM EST
Optimind Pharma Balance Sheet
Financials in millions CAD. Fiscal year is March - February.
Millions CAD. Fiscal year is Mar - Feb.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Cash & Equivalents | 0.1 | 0.08 | 0.03 | 0.55 | 1.35 |
Cash & Short-Term Investments | 0.1 | 0.08 | 0.03 | 0.55 | 1.35 |
Cash Growth | 18.62% | 191.94% | -94.80% | -59.16% | - |
Accounts Receivable | 0.04 | 0.04 | 0.02 | 0.03 | - |
Other Receivables | - | 0.03 | 0.14 | 0.08 | 0 |
Receivables | 0.04 | 0.07 | 0.16 | 0.12 | 0 |
Restricted Cash | - | - | - | - | 0.51 |
Total Current Assets | 0.14 | 0.15 | 0.19 | 0.67 | 1.86 |
Property, Plant & Equipment | - | - | - | 0.09 | 0.12 |
Long-Term Investments | - | 0.05 | 0.05 | 0.05 | 0.31 |
Goodwill | - | - | - | - | 0.86 |
Other Intangible Assets | - | - | - | 0.37 | 0.66 |
Total Assets | 0.14 | 0.2 | 0.24 | 1.35 | 3.82 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Accounts Payable | 0.19 | 0.15 | 0.24 | 0.09 | 0.13 |
Accrued Expenses | 0.02 | - | - | - | - |
Short-Term Debt | 0.12 | 0.13 | 0.13 | 0.5 | - |
Current Portion of Leases | - | - | - | 0.03 | 0.02 |
Other Current Liabilities | - | - | - | - | 0.51 |
Total Current Liabilities | 0.33 | 0.27 | 0.37 | 0.62 | 0.66 |
Long-Term Leases | - | - | - | 0.08 | 0.11 |
Long-Term Deferred Tax Liabilities | - | - | - | 0.01 | 0 |
Total Liabilities | 0.33 | 0.27 | 0.37 | 0.71 | 0.78 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Common Stock | 4.8 | 4.79 | 4.52 | 4.02 | 3.39 |
Additional Paid-In Capital | 0.01 | 0.01 | 0.01 | 0.04 | - |
Retained Earnings | -5.16 | -5.04 | -4.82 | -3.43 | -0.35 |
Comprehensive Income & Other | 0.16 | 0.16 | 0.16 | - | - |
Shareholders' Equity | -0.19 | -0.07 | -0.13 | 0.64 | 3.04 |
Total Liabilities & Equity | 0.14 | 0.2 | 0.24 | 1.35 | 3.82 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
Total Debt | 0.12 | 0.13 | 0.13 | 0.61 | 0.13 |
Net Cash (Debt) | -0.02 | -0.04 | -0.1 | -0.06 | 1.22 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.00 | -0.00 | -0.00 | -0.00 | 0.03 |
Filing Date Shares Outstanding | 103.15 | 103.15 | 116.89 | 97.93 | 43.59 |
Total Common Shares Outstanding | 103.15 | 109.79 | 116.89 | 97.93 | 43.59 |
Working Capital | -0.19 | -0.12 | -0.18 | 0.04 | 1.2 |
Book Value Per Share | -0.00 | -0.00 | -0.00 | 0.01 | 0.07 |
Tangible Book Value | -0.19 | -0.07 | -0.13 | 0.27 | 1.52 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | 0.00 | 0.03 |